Literature DB >> 9242610

An antagonist decoy receptor and a death domain-containing receptor for TRAIL.

G Pan1, J Ni, Y F Wei, G Yu, R Gentz, V M Dixit.   

Abstract

TRAIL, also called Apo2L, is a cytotoxic protein that induces apoptosis of many transformed cell lines but not of normal tissues, even though its death domain-containing receptor, DR4, is expressed on both cell types. An antagonist decoy receptor (designated as TRID for TRAIL receptor without an intracellular domain) that may explain the resistant phenotype of normal tissues was identified. TRID is a distinct gene product with an extracellular TRAIL-binding domain and a transmembrane domain but no intracellular signaling domain. TRID transcripts were detected in many normal human tissues but not in most cancer cell lines examined. Ectopic expression of TRID protected mammalian cells from TRAIL-induced apoptosis, which is consistent with a protective role. Another death domain-containing receptor for TRAIL (designated as death receptor-5), which preferentially engaged a FLICE (caspase-8)-related death protease, was also identified.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9242610     DOI: 10.1126/science.277.5327.815

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  364 in total

Review 1.  Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.

Authors:  B G Darnay; B B Aggarwal
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Apoptosis and cancer drug targeting.

Authors:  W R Sellers; D E Fisher
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

3.  TVB receptors for cytopathic and noncytopathic subgroups of avian leukosis viruses are functional death receptors.

Authors:  J Brojatsch; J Naughton; H B Adkins; J A Young
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Mechanisms of apoptosis.

Authors:  J C Reed
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

5.  Identification of death receptors DR4 and DR5 in HTB-12 astrocytoma cell lines and determination of TRAIL sensitivity.

Authors:  Elenia Riddick; Shavonda Evans; Jeffrey Rousch; Ephraim Gwebu; Hirendra Nath Banerjee
Journal:  J Solid Tumors       Date:  2013-12-01

Review 6.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

7.  Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.

Authors:  Vassiliki Poulaki; Constantine S Mitsiades; Vassiliki Kotoula; Sophia Tseleni-Balafouta; Avi Ashkenazi; Demetrios A Koutras; Nicholas Mitsiades
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

8.  Results on efficacy and safety of cancer treatment with or without tumor necrosis factor-related apoptosis-inducing ligand-related agents: A meta-analysis.

Authors:  Shaoxing Sun; Zonghuan Li; Li Sun; Chunxu Yang; Zijie Mei; Wen Ouyang; Bo Yang; Conghua Xie
Journal:  Mol Clin Oncol       Date:  2014-02-18

9.  Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5.

Authors:  Tai-Guang Jin; Alexei Kurakin; Nordine Benhaga; Karon Abe; Mehrdad Mohseni; Ferry Sandra; Keli Song; Brian K Kay; Roya Khosravi-Far
Journal:  J Biol Chem       Date:  2004-10-14       Impact factor: 5.157

Review 10.  Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.

Authors:  Nor Saadah M Azahri; Mary M Kavurma
Journal:  Cell Mol Life Sci       Date:  2013-01-18       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.